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Novel and emerging tobacco products have presented a number of challenges for regulators, including the risk that regulation may lead to litigation. This paper analyses 
litigation concerning tobacco product regulation across 
jurisdictions, with the aim of highlighting the legal 
arguments advanced and the reasoning of courts relevant 
to novel and emerging nicotine and tobacco products.
Two broad categories of litigation can be identified. 
The first concerns measures addressing product 
characteristics and disclosures. This group of cases 
concerns legal challenges against measures which 
prescribe the form that a product may or may not 
take, including, classification of these products 
under national legislation, proportionality of product 
prohibitions, and flavour bans. The second category 
of cases concerns health claims and advertising, 
promotion and sponsorship. These concern application 
of laws to different products, including enforcement 
actions concerning misleading conduct and restrictions 
on advertising, promotion, and sponsorship.
Key findings
The key findings for the purposes of regulation of novel and emerging nicotine and tobacco products are as follows:
 manufacturers of e-cigarettes and heated 
tobacco products attempt to avoid products 
being regulated, so as to effectively fall 
within regulatory or legislative gaps;
 manufacturers can be expected to 
deploy arguments concerning the 
relative risk of different product 
categories, and the need for coherent 
regulation along a continuum of risk;
 not all courts are receptive to 
arguments about relative risk, either 
because regulations are justified by 
reference to absolute risk or because 
the concept of relative risk is judged at 
the population level and taking into 
account factors beyond relative toxicity;
 technological advances employed for 
the manufacture of novel and emerging 
nicotine and tobacco products will raise 
questions of whether a product falls 
within the ambit and scope of the 
national legislation of the country;
 there are relatively few cases 
addressing misleading marketing of 
novel and emerging products, or 
enforcing restrictions on advertising, 
promotion and sponsorship, but 
important cases have been decided, 
including on how social media posts 
may constitute advertising and on 
whether advertising of a heated tobacco 
product device also constitutes 
advertising of a tobacco product.
Together, the cases described offer governments an idea of the legal arguments that have been used in attempts to 
evade or minimize regulation, as well as how courts have addressed those arguments. For ease of access, those 
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In recent years, regulation of novel and emerging nicotine and tobacco products has taken on increased importance in the context of tobacco control. The emergence of products such as heated 
tobacco products (HTPs) and electronic nicotine 
delivery systems (ENDS) and their market growth has 
raised questions about how they should be regulated 
and how that regulation might affect comprehensive 
tobacco control. WHO has previously published its 
position on regulation of these products, but has not 
addressed legal issues, such as how those regulations 
are being challenged in different jurisdictions.
HTPs produce aerosols containing nicotine and toxic 
chemicals when tobacco is heated or when a device 
containing tobacco is activated.1 HTPs contain tobacco 
and are tobacco products and therefore subject to 
the provisions of the WHO Framework Convention on 
Tobacco Control (WHO FCTC).2 Consequently, Parties 
to the Convention are legally obliged to implement 
measures including regulating product contents and 
disclosures (Articles 9 and 10), banning or restricting 
advertising, promotion and sponsorship (Article 13) and 
regulating labelling (Article 11).
ENDS are devices that heat a liquid solution to create 
an aerosol that is inhaled by the user.3 ENDS is an 
all-encompassing term for multiple product categories: 
e-cigarettes, vapes, vape pens, e-cigars, e-hookahs, 
and e-pipes.4 There are other electronic, non-nicotine 
delivery systems (ENNDS), which do not contain 
nicotine.5 For the purposes of this report, ENDS, 
includes ENNDS unless otherwise specified.
In the context of ENDS, where they are not prohibited, 
WHO has recommended that Member States regulate 
the products as tobacco products, medicinal products, 
consumer products, or other categories, as appropriate, 
taking into account a high level of protection for human 
health. WHO has recommended that Member States 
pursue the following general regulatory objectives:
General regulatory 
objectives
 impeding ENDS promotion to and uptake by 
non-smokers, pregnant women and youth;
 minimizing potential health risks to ENDS 
users and non-users;
 prohibiting unproven health claims from 
being made about ENDS; and
 protecting existing tobacco-control efforts 
from commercial and other vested interests 
of the tobacco industry.6
WHO has also recommended that in order to achieve 
these objectives, Member States that have not banned 
the importation, sale, and distribution of ENDS/ENNDS 
should consider a list of non-exhaustive regulatory 







Box 1. Regulatory options for Member States that 
have not banned ENDS/ENNDS
Prevent the initiation of ENDS/ENNDS by non-smokers and  
youth with special attention to vulnerable groups.
a   Banning the sale and distribution of ENDS/
ENNDS to minors;
b   Banning the possession of ENDS/ENNDS by 
minors;
c   Banning or restricting advertising, promotion 
and sponsorship of ENDS/ENNDS (see FCTC/
COP/6/10 Rev.1 discussed below);
d   Taxing ENDS/ENNDS at a level that makes the 
devices and e-liquids unaffordable to minors in 
order to deter its use in this age group. 
In parallel, combustible tobacco products 
should be taxed at a higher level than ENDS/
ENNDS to deter initiation and reduce 
regression to smoking;
e   Banning or restricting the use of flavours that 
appeal to minors;
f   Regulating places, density and channels of 
sales; and
g   Taking measures to combat illicit trade in 
ENDS/ENNDS.
Minimize as far as possible potential health risks to ENDS/ENNDS users  
and protect non-users from exposure to their emissions.
a   To minimize health risks to users:
i. Testing heated and inhaled flavourants used in 
the e-liquids for safety, and banning or restricting 
the amount of those found to be of serious 
toxicological concern such as diacetyl, acetyl 
propionyl, cinnamaldehydes or benzaldehyde;
ii. Requiring the use of ingredients that are not 
a risk to health and are, when allowed, of the 
highest purity;
iii. Regulating electrical and fire safety standards 
of ENDS/ENNDS devices;
iv. Regulating the need for manufacturers to 
disclose product content to government;
v. Regulating appropriate labelling of devices and 
e-liquids;
vi. Requiring manufacturers to monitor and report 
adverse effects; and
vii. Providing for the removal of products that do 
not comply with regulations.
b   To minimize health risks to non-users:
i. Prohibiting by law the use of ENDS/ENNDS in 
indoor spaces or at least where smoking is not 
permitted;
ii. Requiring health warnings about potential 
health risks deriving from their use. Health 
warnings may additionally inform the public 
about the addictive nature of nicotine in ENDS; 
and
iii. Reducing the risk of accidental acute nicotine 
intoxication by (a) requiring tamper evident / 
child resistant packaging for e-liquids and leak-
proof containers for devices and e-liquids and 
(b) limiting the nicotine concentration and total 
nicotine amount in devices and e-liquids.
Introduction and scope
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Some WHO Member States regulating ENDS have 
been challenged in international and domestic legal 
proceedings. With a view to capture this experience, 
this paper sets out a comparative analysis of litigation 
concerning novel and emerging nicotine and tobacco 
product regulation. The experience with regulation 
of cigarettes shows that tobacco companies make 
similar arguments across different jurisdictions and 
that comparative analysis of those arguments can help 
regulators anticipate litigation and address the risks 
associated with such litigation. Accordingly, this paper 
is intended to assist Member States to achieve a high 
level of health protection in the context of ENDS and 
HTPs through a discussion on the legal challenges 
arising globally, arguments advanced therein, and 
reasoning of the courts to enable policymakers to 
design regulatory approaches that also withstand 
legal scrutiny.
Box 1. Regulatory options for Member States that 
have not banned ENDS/ENNDS (continued)
Prevention of unproven health claims being made about ENDS/ENNDS.
 Prohibiting implicit or explicit claims about the 
effectiveness of ENDS/ENNDS as smoking 
cessation aids unless a specialized 
governmental agency has approved them;
 Prohibiting implicit or explicit claims that 
ENDS/ENNDS are innocuous or that ENDS are 
not addictive; and
 Prohibiting implicit or explicit claims about the 
comparative safety or addictiveness of ENDS/
ENNDS with respect to any product unless 
these have been approved by a specialized 
governmental agency.
Protect tobacco control activities from all commercial and other vested 
interests related to ENDS/ENNDS, including interests of the tobacco industry.
 Raising awareness about potential industry 
interference with Parties’ tobacco control 
policies;
 Establishing measures to limit interactions 
with the industry and to ensure transparency 
in those interactions that do take place;
 Rejecting partnerships with the industry;
 Taking measures to prevent conflicts of 
interest for government officials and 
employees;
 Requiring that information provided by the 
industry be transparent and accurate;
 Banning activities described as “socially 
responsible” by the industry, including but not 
limited to activities described as “corporate 
social responsibility”;
 Refusing to give preferential treatment to 
industry; and
 Treating State-owned industry in the same way 















Relevant judicial decisions and administrative proceedings (together referred to as cases) have been identified primarily through the Tobacco Control Laws database (https://
www.tobaccocontrollaws.org/litigation) and 
LexisNexis. A handful of cases not in the database, 
but known to the authors through engagement with 
Member States, have also been included in this paper.
As of 10 November 2020, the Tobacco Control Laws 
database contains 1065 cases dating back to 1968. 
Accordingly, the scope of the review and analysis is 
limited to novel and emerging nicotine and tobacco 
products, in order to focus on contemporary issues in 
product regulation, rather than on legal challenges to 
tobacco control more generally. Product regulation 
can be a broad concept, encompassing regulation of 
the manufacture, presentation and content of products, 
to reduce demand, supply or to improve safety. 
Recognizing the breadth of this concept, the analysis 
is focused primarily on the regulation of ENDS and 
HTPs, including how these products might be classified 
under existing laws or new legislation to be introduced 
by Member States, and the extent to which such 
regulation is coherent with approaches to other novel 
and emerging nicotine or tobacco products. In this 
regard, 89 cases between 2008-2020 were identified 
as relevant.
Another limitation on the scope of this paper is that 
challenges to generally applicable tobacco control 
laws, or to general packaging and labelling laws, 
are excluded in the absence of an argument with 
broader implications for product regulation. Although 
this approach necessarily involves some element of 
editorial discretion, it enables identification of common 
arguments or issues that can be taken into account in 
the legislative or regulatory process.
Finally, in many instances official English language 
translations of court decisions are not available. 
However, Google Translate was used, where necessary, 
to review decisions in other languages, especially in the 
absence of unofficial translations. This limits the detail 
of the discussion on specific cases.
These categories of cases are described in more 
detail below with the final caveat that the description 
is focused more on the arguments raised and types 
of challenges brought rather than on the legal 
analysis offered by the courts. This approach assumes 
that the conclusions drawn by the courts in the 
cases mentioned below are often particular to the 
jurisdictions in question, but that lessons can be drawn 
from commonalities found in the arguments raised.
The scope of the review and analysis is limited to novel 
and emerging nicotine and tobacco products, in order 
to focus on contemporary issues in product regulation.
Product characteristics and disclosures
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Litigation in the context of product characteristics and 
disclosures primarily concerns prohibition of product 
categories and measures prescribing the form that 
a product must or may take. This includes claims 
challenging the following:
 classification of ENDS and other products 
as drugs;
 classification of smokeless tobacco products 
as food;
 prohibitions (whether legislated or the result 
of administrative decision-making) on 
constitutional grounds; and
 prohibition of flavoured ENDS and non-
nicotine flavourings.
Together, these cases highlight how both ENDS and 
HTP manufacturers use litigation in attempting to 
fall between regulatory regimes, effectively evading 
regulation either as tobacco products or other 
regulated goods. Where the cases go beyond product 
classification, questions of regulatory authority and 
interpretation of statutory definitions, they foreshadow 
some of the arguments that governments can expect 
once ENDS or HTPs are subjected to tobacco control 
or other laws and regulations. In this respect, a series 
of claims relating to the prohibition of snus in the 2014 
EU Tobacco Products Directive9 shows the types of 
constitutional law arguments that might be invoked in 
challenges. One striking aspect of these cases is how 
arguments about the relative harmfulness of different 
product categories are deployed in challenging the 
proportionality of product prohibitions.
9 Official Journal of the European Union, Directive 2014/40/EU, April 3, 2014, (https://ec.europa.eu/health/sites/health/files/tobacco/docs/dir_201440_
en.pdf, accessed 3 August 2020)
10 FCTC/COP8(22), n (2)
11 ibid, para 3 (b)
Classification hurdles 
under existing laws
In many countries, ENDS and HTPs have entered the 
market in the absence of specific legal or regulatory 
regimes to govern them, leaving governments to 
apply existing laws, amend existing laws, or permit the 
products to fall within legislative or regulatory gaps. 
In a number of countries, litigation has arisen with 
economic operators challenging how either ENDS or 
HTPs have been classified under existing laws.
Before these cases are described, it is also worth 
noting that there are two ongoing international legal 
processes that could affect product classification under 
domestic laws. First, the Secretariat of the WHO FCTC 
has been requested to report back to the Ninth session 
of the Conference of the Parties (COP) to the WHO 
FCTC on appropriate classification of HTPs to support 
regulatory efforts and define new product categories.10 
This decision also recognized HTPs as tobacco products 
under the WHO FCTC, but did not equate them with a 
single type of tobacco product, such as cigarettes or 
any other type of tobacco product.11 It is reasonable 
to expect that some Parties to the Convention may 
use guidance from the COP in classifying HTPs under 
existing domestic tobacco control laws. For example, 
classification by the COP may affect application of 
tobacco control laws where different product categories 
are subject to different laws on tax or labelling.
Secondly, the World Customs Organization is facilitating 
revision of the Harmonized System Code to create new 
customs codes for novel nicotine and tobacco products, 
including HTPs and ENDS. Amendments to chapter 
24 of the HS Code will create a new heading 24.04 for 









and sub-headings for those containing tobacco 
(2404.11), such as HTPs, and those containing nicotine 
(2404.12), such as ENDS. Other nicotine products, such 
as nicotine replacement therapies, will also be included 
in chapter 24, but under separate sub-headings. 
Amendments to the HS Code will be reflected in 
domestic customs codes no later than January 2022.12 
This may affect application of domestic tobacco tax 
laws, such as where those laws define taxable goods 
and/or applicable rates by reference to customs codes.
In the context of ongoing classification processes, it is 
worth examining legal disputes that have arisen to date.
One example of a classification case is New Zealand 
Ministry of Health v Philip Morris (New Zealand) Ltd.13 
This case concerned an enforcement action by the New 
Zealand government against Philip Morris concerning 
sale of ‘Heets’, to be used in an HTP device. Under the 
Smoke Free Environment Act (1990) it was prohibited 
to, among other things, import or sell any product 
labelled or otherwise described as suitable for chewing, 
or for any other oral use (other than smoking). The 
government alleged that Heets constituted a tobacco 
product for oral use other than smoking as it was 
not ignited but heated and that importation and sale 
were, therefore, prohibited. Philip Morris argued that 
oral use was intended to refer to chewing tobacco 
and similar products taken orally, and that ‘Heets’ did 
not fall within the scope of the definition (Rather than 
argue that the products were prepared for smoking, 
the company argued that they fell within a legislative 
gap). The Court agreed with Philip Morris, concluding 
that the legislative intent was to prohibit products used 
for chewing or similar activities. In February 2020, a bill 
was introduced to amend the Smoke Free Environment 
Act (1990) in order to bring the provisions of the Act 
up to date and ensure that all regulated products were 
covered within its ambit. A definition for heated tobacco 
products was included through the amendment: ‘a 
smokeless tobacco product that has a device that uses 
or facilitates the use of heat to aerosolise nicotine from 
tobacco leaf directly’.14 The Amendment Bill received 
royal assent on 11 August, 2020.
In Israel, while the government was developing legislation 
to govern ENDS, a company applied for permission 
12 World Customs Organization, ‘The new 2022 Edition of the Harmonized System has been accepted’, January 8, 2020, (http://www.wcoomd.org/en/
media/newsroom/2020/january/the-new-2022-edition-of-the-harmonized-system-has-been-accepted.aspx, accessed 4 August 2020) 
13 District Court at Wellington, Ministry of Health v Phillip Morris (New Zealand) Limited, [2018] NZDC 4478, (https://www.tobaccocontrollaws.org/files/
live/litigation/2632/NZ_New%20Zealand%20MOH%20v.%20PMI.pdf, accessed 27 June 2019)
14 New Zealand Legislation, Smoke free Environment and Regulated Products (Vaping) Amendment Bill: Section 2, (http://legislation.govt.nz/bill/
government/2020/0222/latest/LMS313857.html, accessed 13 August 2020) 
15 The Israel Supreme Court, E-Cig Ltd. v Ministry of Health, [2014] HCJ 6665/12, (https://www.tobaccocontrollaws.org/files/live/litigation/2217/IL_E-
Cig%20Ltd.%20v.%20Ministry%20of%20Heal.pdf, accessed 27 June 2019)
16 The Israel Supreme Court, Tel Aviv Chamber of Commerce v Israeli Knesset & Ors., [2019] HC 4657/19 and HC 1532/19, (https://www.
tobaccocontrollaws.org/files/live/litigation/2711/IL_The%20Tel%20Aviv%20Chamber%20of%20Commer.pdf, accessed 15 May 2020)
17 Ministry of Law and Justice, No. 342 of 2019, (http://www.prsindia.org/sites/default/files/bill_files/Prohibition%20of%20Electronic%20Cigarettes%20
Ordinance%2C%202019.pdf, accessed 17 July 2020)
to import and market an e-cigarette. The government 
rejected the request on grounds that the efficacy and 
safety of the product were not proven, and that import 
was thereby inconsistent with the Pharmacists Ordinance. 
This led to E-Cig Ltd. v Ministry of Health15, in which the 
decision was challenged on grounds that e-cigarettes 
are recreational products rather than pharmaceuticals. 
The court agreed, holding that there was no basis in 
the Ordinance for the decision to apply to e-cigarettes.
In December 2018, the Israeli legislature passed a new law 
governing both tobacco products and ENDS. JUUL Labs 
challenged provisions of the new legislation that stipulated 
restrictions on advertising of ENDS and application of 
tobacco plain packaging to ENDS. A similar challenge was 
brought by the Tel Aviv Chamber of Commerce (Chamber). 
The main argument advanced by the Chamber was 
that vaping products are less harmful than tobacco 
smoking products and should encourage regular 
smokers to switch to vaping. Accordingly, prohibitions 
and restrictions on the advertising of vaping products 
violate the freedom of occupation of the Members of the 
Chamber. JUUL Labs withdrew its petition days before 
the hearing, followed by a withdrawal by the Chamber.16
The ENDS classification disputes in India ended in 
December 2019 with the enactment of legislation to 
prohibit the production, manufacture, import, export, 
transportation, sale, distribution, advertisement, and 
promotion of electronic cigarettes.17 The law includes 
a broad definition of electronic cigarettes that includes 
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ENDS, HTPs, and other similar devices.18 In the process 
of passing this legislation, India defended a few legal 
challenges concerning the classification of ENDS. At the 
beginning of the policy process, the Ministry of Health 
and Family Welfare issued an advisory which stipulated 
that ENDS and HTPs should not, among other things, be 
traded or advertised except where approved under the 
Drugs and Cosmetics Act 1940. This was challenged 
by an importer in M/s Focus Brands v Directorate of 
Health Services and Ors. The High Court of Delhi stayed 
operation of the advisory on the basis that these products 
do not fall within the definition of drugs under the Act of 
1940.19 Following the advisory issued by the Ministry of 
Health and Family Welfare, 12 states in India undertook 
steps to ban the use of ENDS: Punjab & Haryana, 
Maharashtra, Karnataka, Kerala, Bihar, Uttar Pradesh, 
Jammu & Kashmir, Himachal Pradesh, Tamil Nadu, 
Puducherry, and Jharkhand.20 Thereafter, in September 
2019, the Central Government promulgated an ordinance.21 
Two writ petitions were filed against the Ordinance 
claiming that it infringed the right of the user to choose 
a less harmful alternative (i.e. ENDS) to combustible 
cigarettes. 22 The claims were dismissed on the ground 
that the Ordinance passed the scrutiny of both the Houses, 
to become an Act of Parliament. In the circumstances, 
nothing remained for adjudication in the writ petitions.23
The Indian ENDS classification cases have similarities 
with a number of Indian cases concerning the smokeless 
tobacco products gutka, pan masala, and zarda. In this 
context, 23 states and 5 union territories have prohibited 
these products under the food law. A number of claims 
have challenged the classification of these products 
as food, leading to a series of pending claims before 
the Supreme Court of India in Central Arecanut Co. & 
Ors. v Union of India.24 The Ministry of Health & Family 
Welfare brought to the notice of the Supreme Court 
that the manufacturers in order to circumvent the 
ban were selling pan masala (without tobacco) along 
with flavoured chewing tobacco in separate sachets. 
The central question is whether powers under India’s 
food law extend to the separate packages of tobacco. 
18 ibid, Section 3(d)
19 The High Court of Delhi, M/s Focus Brands v Directorate of Health Services and Ors, [2019] Writ Petition (Civil) 2688/2019, (http://delhihighcourt.nic.
in/dhcqrydisp_o.asp?pn=60136&yr=2019, accessed 3 May 2019)
20 Live Mint, ‘12 states ban e-cigarettes, health ministry urges all to follow’, Neetu Chandra Sharma, March 13, 2019, (https://www.livemint.com/news/
india/12-states-ban-e-cigarettes-health-ministry-urges-all-to-follow-1552447122172.html, accessed 2 September 2019) 
21 Ministry of Law and Justice, No. 14 of 2019, (https://www.prsindia.org/sites/default/files/bill_files/Prohibition%20of%20Electronic%20Cigarettes%20
Ordinance%2C%202019.pdf, accessed 17 July 2020)
22 The High Court of Calcutta, Plume Vapour Private Ltd. & Anr. v Union of India & Ors. and M/s Woke Vapors Pvt. Ltd. v Union of India & Ors., [2019] A.S.T 
40 and 41, (https://www.calcuttahighcourt.gov.in/Order-Judgment-PDF/A/AST_40_2019_26092019_O_239.pdf, accessed 3 October 2019) 
23 ibid, (https://www.calcuttahighcourt.gov.in/Order-Judgment-PDF/A/AST_40_2019_12122019_O_239.pdf, accessed 15 May 2020)
24 The Supreme Court of India, Central Arecanut Co. & Ors. v Union of India, [2010] Transfer Case (Civil) No. 1, (https://www.tobaccocontrollaws.org/files/
live/litigation/2620/IN_Central%20Arecanut%20Marketing%20Com.pdf, accessed 30 June 2019)
25 The District Court of Hague, X [Company selling e-cigarettes] v The Netherlands, [2008] Case No: KG 08-136, (https://www.tobaccocontrollaws.org/
files/live/litigation/2126/NL_X%20%5BCompany%20selling%20e-cigarette.pdf, accessed 1 July 2019)
26 The District Court of Hague, United Tobacco Vapor Group Inc. v The Netherlands , [2012] Case No.: 414117-KG ZA 12-209, (https://www.
tobaccocontrollaws.org/files/live/litigation/2128/NL_United%20Tobacco%20Vapor%20Group%20Inc.pdf, accessed 22 July 2019)
27 The Hague Court of Appeal, The Netherlands v United Tobacco Vapor Group, [2012] Case No.: 200.105.395-01, (https://www.tobaccocontrollaws.org/
files/live/litigation/2130/NL_The%20Netherlands%20v.%20United%20Toba.pdf, accessed 21 July 2019)
28 2012 FC 1465
29 Section 2(a): the diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state, or its symptoms, in human beings or animals;
A similar question was raised in the context of ban on the 
sale of food flavourings in specialized tobacco shops in 
Finland, discussed in the flavour ban sub-section below.
Prior to the 2014 European Union Tobacco Products 
Directive (EU TPD), the Netherlands also faced 
challenges with respect to classification of ENDS. In 
2007, the government provisionally classified ENDS 
as a medicine and issued a provisional enforcement 
policy that would permit importation without market 
authorization, but would not permit advertising or 
promotion. This provisional policy was first upheld in 
X v The Netherlands25 where the court concluded that 
because nicotine had a stimulating and calming effect 
it could be classified as a medicine. Subsequently, a 
decision of the Minister of Health, Welfare and Sport to 
formally classify ENDS as medicines under the Medicines 
Act was challenged in United Tobacco Vapor Group Inc. 
v The Netherlands.26 At first instance, the District Court 
of The Hague ruled against the government, finding that 
it should have first demonstrated the pharmacological 
effects of ENDS before classifying them as medicines 
under the Act. On appeal, The Hague Court of Appeal27 
also found against the government, concluding that 
ENDS do not constitute a medicine under the Medicines 
Act and that application of the Act in this way created 
obstacles to free movement of ENDS within the EU that 
were not proportionate to the protection of public health.
In Canada before the amendment of the Tobacco Act 
in 2018, which broadened its scope to include vaping 
products, Health Canada’s authority to regulate 
electronic cigarettes as a ‘scheduled drug’ under the 
Food and Drugs Act was in question in Zen Cigarette 
Inc. v Health Canada.28 It was contended by Health 
Canada that as Zen Cigarette’s website claimed that 
electronic cigarettes may assist with tobacco cessation, 
it qualified as a drug under provisions of the Food 
and Drugs Act.29 The Court held that the evidence 
established that Zen promoted electronic cigarettes for 
the treatment of nicotine addiction and thus qualified as 
a drug under Section 2(a) of the Act.
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In many respects, these classification cases are 
similar to the experience in the United States of 
America (US) with Smoking Everywhere Inc. & 
Ors. v FDA30 and Sottera, Inc. v FDA31, in which the 
courts examined whether FDA’s authority to regulate 
electronic cigarettes stemmed from the Federal Food, 
Drug and Cosmetic Act (FDCA) or the Family Smoking 
Prevention and Tobacco Control Act (Tobacco Act). 
Distributors of electronic cigarettes (plaintiffs before 
the District Court) argued that electronic cigarettes 
were a functional equivalent of traditional cigarettes 
and should be regulated under the Tobacco Act. On 
the other hand, FDA argued that the promotional 
materials of the electronic cigarettes suggested that 
e-cigarettes provided a ‘healthier way’ to obtain effects 
of nicotine and intended to alleviate nicotine withdrawal 
symptoms and should be regulated as a drug-
device combination under the FDCA. It was held that 
e-cigarettes could not be brought under the scope of 
the FDCA merely because they delivered nicotine, doing 
so would dismantle the regulatory wall erected by 
Congress between tobacco products and drug-device 
combinations.
These cases were followed by a subsequent challenge 
to the deeming of e-cigarettes (Deeming Rule) as 
tobacco products in Nicopure Labs LLC v FDA.32 The 
short question in this case was whether the FDA 
exceeded its authority in applying the Deeming Rule 
to open-ended devices sold without any liquid and 
e-liquids that did not contain nicotine. The Court 
concluded that FDA acted within the scope of its 
statutory authority by regulating e-liquids as a 
‘component’ of refillable electronic nicotine delivery 
systems. It was observed that given the proliferation of 
ENDS, subjecting these products to a premarket review 
would ensure that fewer harmful or addictive products 
entered the market.
The US cases also foreshadowed the situation in 
Israel where legal challenges arose in the context 
of administrative action to regulate ENDS as drugs, 
and then subsequently when ENDS are regulated as 
tobacco products. In this sense, the challenges pursue 
the common goal of delaying regulation and ensuring 
that ENDS fall through regulatory gaps between the 
legal regimes governing tobacco and drugs.
30 United States District Court, Smoking Everywhere Inc. v FDA, [2010] 680 F.Supp. 2d 62 (Columbia), (https://www.tobaccocontrollaws.org/files/live/
litigation/1493/US_Smoking%20Everywhere%20v.%20Food%20and.pdf, accessed 25 July 2019)
31 United States Court of Appeals, Sottera, Inc. v FDA, [2010] 627 F.3d 891 (Columbia), (https://www.tobaccocontrollaws.org/files/live/litigation/1032/
US_Sottera%20v.%20Food%20%26%20Drug%20Adminis.pdf, accessed 27 June 2019)
32 United States District Court, Nicopure Labs, LLC v Food and Drug Administration, [2017] F.Supp.3d (Columbia), (https://www.tobaccocontrollaws.org/
files/live/litigation/2558/US_Nicopure%20Labs%2C%20LLC%20v.%20Food%20and.pdf, accessed 1 July 2019)
33 See, Directive 2014/40/EU of the European Parliament and of the Council of 3 April 2014, (https://ec.europa.eu/health/sites/health/files/tobacco/
docs/dir_201440_en.pdf, accessed 27 July 2019)
34 Court of Justice of the European Union, Pillbox 38 (UK) Ltd. v Secretary of State for Health, [2016] Case C-477/14, (https://www.tobaccocontrollaws.
org/files/live/litigation/2458/EU_Pillbox%2038%20%28UK%29%20Ltd.%20v.%20Secret.pdf, accessed 27 June 2019)
35 ibid, para 41
Prohibition and 
proportionality
Outside of the context where governments have 
made decisions concerning how to classify products 
under existing laws, a number of cases have arisen 
in which product prohibitions have been challenged. 
Typically, these challenges have included arguments 
that prohibition is not proportionate to the policy 
objective in light of the health risks posed by a specific 
product category.
For example, numerous challenges arose following 
implementation of the 2014 EU TPD. The EU TPD 
required EU Member States to impose requirements 
on e-cigarettes, including maximum nicotine limits, 
child-proof packaging, health warnings and a product 
registration system.33 The validity of these aspects of 
the EU TPD were challenged in the United Kingdom 
by an e-cigarette manufacturer in Pillbox v Secretary 
of State for Health.34 The company challenged these 
rules on a number of grounds under EU law, including 
with respect to proportionality and equal treatment. 
The company also invoked the European Charter of 
Fundamental Rights, arguing that the requirements 
impinged the right to conduct a business and the right 
to property with respect to intellectual property rights. 
The High Court of England and Wales referred the 
matter to the European Court of Justice (ECJ), which 
ultimately upheld the EU TPD.
In considering the question of equal treatment the 
ECJ highlighted that e-cigarettes have different 
characteristics to tobacco products, are used to 
consume nicotine and that their risks to human health 
are not clear.35 Accordingly, they were viewed as being 
in a different situation to tobacco products, such that 
different treatment was justified. The ECJ did not 
engage in a detailed examination of the relative risks 
posed by the different product categories.
On the question of proportionality, the company had 
argued that e-cigarettes are less harmful to health 
than tobacco products and that in this context the 
regulations imposed were not proportionate. In 
examining the issue, the court stressed the high 
standard of proof, which required the company 
Product characteristics and disclosures
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to show that the requirements were manifestly 
inappropriate, emphasized that the EU legislature 
has a broad discretion and also relied on the 
precautionary principle.36 In light of mixed evidence 
on the risks posed by e-cigarettes the ECJ held that 
application of the requirements was proportional and 
justified. Having found that the requirements were 
proportionate, the ECJ also rejected the arguments 
relating to freedom to conduct a business. Separately, 
the court concluded that intellectual property rights 
were not affected.
The requirements imposed on e-cigarettes under the 
EU TPD can be contrasted with snus, which EU Member 
States, with the exception of Sweden, are required 
to prohibit. This led the company Swedish Match to 
challenge the ban and also led to claims in Switzerland 
and Norway, which are not EU Member States.
In Case C-151/17 Swedish Match, challenged the EU 
TPD ban on snus despite the fact it had been found 
valid in an earlier case (C-210/03) concerning the 2001 
EU TPD.37 The 2017 challenge was presented in light of 
new evidence on the relative harmfulness of snus from 
Sweden and Norway, as well as the introduction of 
ENDS, such as e-cigarettes, and novel tobacco products 
into the EU.
Swedish Match argued that the prohibition on snus 
violates the principle of equal treatment, which 
requires that comparable situations must not be 
treated differently unless objectively justified. The 
company argued that this principle was violated 
because other smokeless products, cigarettes, ENDS 
and novel tobacco products are permitted on the 
market. The European Court of Justice (ECJ) rejected 
this argument, concluding that the:
 l evidence suggests snus would be attractive to 
young people and has considerable potential for 
market expansion, thereby justifying different 
treatment from cigarettes and smokeless products;
 l objective characteristics of ENDS differ from 
tobacco products, justifying different treatment; 
and
 l effects of novel tobacco products on health could 
not be observed when the EU TPD was adopted, 
whereas the effects of snus had been scientifically 
substantiated.
36 ibid, para 51-55
37 Court of Justice of the European Union (CJEU), Swedish Match AB v Secretary of State for Health, [2018] Case C-151/17, (http://curia.europa.eu/juris/
document/document.jsf?text=&docid=207969&pageIndex=0&doclang=EN&mode=lst&dir=&occ=first&part=1&cid=16669669, accessed 14 September 2020)
38 Federal Court of Switzerland, Gmbh v Customs Inspectorate Basel, [2019] 2C_718/2018, (https://www.bger.ch/ext/eurospider/live/de/php/aza/http/
index.php?highlight_docid=aza%3A%2F%2Faza://27-05-2019-2C_718-2018&lang=de&zoom=&type=show_document, accessed 27 June 2019)
Swedish Match also argued that the obligation to 
prohibit snus is invalid as it violates the principle 
of proportionality. The ECJ rejected this argument, 
concluding that the prohibition was not manifestly 
inappropriate. The Court noted the relevance of the 
precautionary principle and based its conclusion partly 
on the risk that the attractiveness of snus to young 
people might create a gateway effect. Having rejected 
the argument concerning equal treatment, the court 
also rejected the argument that the different treatment 
of other products showed the prohibition on snus to 
be disproportionate.
In GmbH v. Customs Inspectorate Basel38 similar 
arguments were made concerning a national level 
ban on snus in Switzerland, which has both ENDS and 
HTPs in its market. The Swiss courts were called upon 
to determine the constitutionality of an import ban 
implemented through an ordinance prohibiting tobacco 
products for oral use. The court considered the legislative 
basis for the Ordinance under the Foodstuff and Utility 
Articles Act and held that the Act only provided a basis 
to ban goods that endangered health in unexpected ways, 
whereas the health hazards of tobacco were well known. 
The court found that it need not consider arguments 
concerning proportionality or the public interest.
The Court also touched on the arguments concerning 
relative risk and stated that it was arbitrary and illegal 
(in the context of constitutionally guaranteed economic 
freedoms) to prohibit snus when more dangerous 
products like cigarettes were not prohibited. The Court 
reasoned that even in the European Union, the ban on 
snus did not apply to Sweden. Thus, it was unclear why 
a ban on snus would be required in Switzerland, for 




arguments that prohibition is 
not proportionate to the policy 
objective in light of the health 




Finally, in Swedish Match v The Ministry of Health & 
Care Services39 the company challenged the legality 
of tobacco plain packaging to snus in Norway. The 
Norwegian regulations on plain packaging apply to 
cigarettes, roll-your-own tobacco and snus. They 
do not apply to cigars or ENDS, even though the 
regulatory power exists for the Minister to extend 
plain packaging to those product categories. Plain 
packaging was also introduced simultaneously to the 
lifting of a prohibition on ENDS in order for Norway 
to implement provisions of the 2014 EU TPD (under 
Norway’s European Free Trade Area commitments to 
the EU).
Swedish Match challenged the plain packaging 
regulation on grounds that it was not proportionate. 
The company argued that there was no factual basis 
for extending the regulations to snus as the evidence 
underpinning plain packaging was specific primarily 
to cigarettes. Norway relied on an expert report in 
arguing that snus was particularly attractive to youth 
and that rates of snus use were increasing among 
youth. Swedish Match also sought to compare snus to 
cigarettes, as a ‘reduced harm’ product, and ENDS, for 
which there is less evidence of relative risk.
In considering the proportionality argument, the 
Oslo County Court and then Court of Appeal both 
recognized that a margin of appreciation needs to 
be afforded to the state on questions of health. The 
courts focused primarily on the appropriateness 
of imposing plain packaging on snus, rather than 
on the relative treatment of ENDS. Nonetheless, 
the differential treatment of ENDS was considered 
justifiable by reference to the differences between the 
product categories and differences in the evidence base 
concerning youth use.
Viewing these cases together, it is apparent that 
courts applying EU law are reluctant to engage in 
arguments concerning the justification for treating 
product categories differently. Rather, they are 
inclined to focus more narrowly on whether the 
regulations in question are proportionate to the risks 
posed by the products in question and to afford a 
broad margin of appreciation to the EU parliament 
and regulators.
Some of these cases point to broader issues likely to 
arise in future challenges, including:
39 Oslo County Court, Swedish Match v The Ministry of Health & Care Services, [2017] Case No. 17-110415TVI-OBYF, (https://www.domstol.no/
globalassets/upload/obyf/internett/aktuelt/kjennelser/17-110415tvi_swedish-match-ab.pdf, accessed 9 July 2018)
40 Supreme Court of Justice of the Nation (Mexico), Neri, José Armando Contreras v Mexico, [2015] Revision 513/2015, (https://www.tobaccocontrollaws.
org/files/live/litigation/2642/MX_Neri%2C%20Jos%C3%A9%20Armando%20Contreras%20.pdf, accessed 27 June 2019)
41 The Finland Tobacco Act (No. 549/2016), (https://www.tobaccocontrollaws.org/files/live/Finland/Finland%20-%20Tobacco%20Act%20%28No.%20
549_2016%29.pdf, accessed on 18 May 2020) 
42 SKA Liquids: ITA Finland Administrative Court, 19/0482/1, [2019]; Striker Finland Oy: Decision of the Administrative Court of Turku, 19/0345/1, [2019]; 
and Salon Höyry Oy: Decision of the Administrative Court of Turku, 20/0056/1, [2020]
 the relative regulatory treatment of one 
product compared to other products and how 
this is justified;
 questions of the relative harmfulness of 
different product categories; and
 the potential for a challenge to the regulatory 
treatment of one product category to open up 
questions concerning regulation of all tobacco 
and nicotine products that may push 
governments towards adopting a ‘continuum 
of risk’ approach to regulation.
This final point, concerning regulation based on a 
continuum of risk, is also borne out in a Mexican case in 
which a provision designed to prevent so-called brand-
stretching was considered. In Neri, José Armando 
Contreras v. Mexico40, the Federal Commission for the 
Protection against Sanitary Risks (Cofepris) imposed 
a fine on a merchant offering electronic cigarettes in a 
commercial establishment. The fine found its basis in 
the General Law on Tobacco Control, which prohibited, 
among other things, the sale of objects containing the 
brand elements of tobacco products or any design or 
symbol identifying the object with tobacco products. 
The merchant argued that this fine amounted to 
unequal treatment before the law because it was 
permissible to sell tobacco products. The court sought 
to balance the interests underpinning the right to 
health with the right to conduct a business and found 
against Cofepris, concluding that applying the tobacco 
control law in this way was excessive.
Flavour bans
In Finland, Section 24 of the Tobacco Act states 
that nicotine-containing liquids intended for use 
in electronic cigarettes, may only be sold or 
supplied to consumers if the liquid does not have 
characteristics or contain additives that are prohibited 
in tobacco products.41 Section 25 of the Act extends 
this requirement to nicotine-free liquids intended 
for vaporization as well. Municipalities in Finland 
prohibited the sale of flavouring liquids (including food 
flavourings) to be sold in vape shops. This prohibition 
has been challenged by owners of specialized vape 
shops as violative of the freedom of movement 
under Article 24 of the EU TPD and the principle of 






in Salon Höyry Oy held that permissibility of sale of 
liquid food flavour concentrates was to be assessed 
based on the conditions and context of supply of the 
products. In a specialty e-cigarette shop, liquid food 
flavour concentrates were suitable for vaporization in 
connection with the main product of the specialty shop 
as its flavour and the prohibition by the Construction 
and Environment Board of Salo was upheld. On the 
other hand, a similar prohibition stipulated by the 
City of Kotka Environmental Board was annulled by 
the Supreme Administrative Court on the ground 
that Finland’s Ministry of Employment and Economy 
failed to notify the EU Commission with the final text 
of the Tobacco Act.43 Section 25 of the Tobacco Act, 
which prohibits characterizing flavor or aroma for 
nicotine-free liquids intended for vaporisation is a 
technical regulation which had not been notified to 
the Commission in accordance with Article 5 (3) of the 
Technical Regulations Directive (2015/1535 / EU). Thus, 
it was held by the Supreme Administrative Court that 
section 25 of the Tobacco Act was not applicable to 
SKA Liquids Oy. However, the court did not rule on 
the question raised by the manufacturer, i.e. whether 
the prohibited liquids were intended for vaporization in 
e-cigarettes and whether the municipality had the right 
to issue the prohibition under the Tobacco Act.
During the EVALI (e-cigarette or vaping product use-
associated lung injury) outbreak in the US, eight states: 
Massachusetts, Michigan, Montana, New York, Oregon, 
Rhode Island, Utah, and Washington, promulgated 
emergency regulations to ban the sale of flavoured 
e-cigarettes.44 The emergency regulations in New York 
carved an exception for e-liquids that are tobacco 
flavoured, menthol, or flavourless, Massachusetts 
enacted a broader ban that applied to all nicotine-
vaping products, and Rhode Island excluded tobacco 
flavoured and unflavoured vaping products.45 The 
emergency regulations were challenged by a vapor 
association alleging that the Health Councils’ in each of 
the States’ overstepped their authority in enacting the 
emergency regulations.46 On the exception for tobacco 
flavour and menthol in New York, it was observed by 
the Court that the emergency regulation carves out 
an exception without any evidence that these flavours 
have been eliminated from the list of substances 
shown to trigger the spate of pulmonary diseases in 
New York.47 Accordingly, it was held that the emergency 
43 Supreme Administrative Court, SKA Liquids, KHO: 2020:77, (https://www.kho.fi/fi/index/paatokset/vuosikirjapaatokset/1592891459008.html, accessed 
3 November 2020)
44 See Campaign for Tobacco-Free Kids, States & Localities that have restricted the sale of flavoured tobacco products, May 8, 2020, (https://www.
tobaccofreekids.org/assets/factsheets/0398.pdf, accessed 21 May 2020)
45 Supreme Court of New York, Matter of Vapor Tech. Assn. v Cuomo, [2020] 118 N.Y.S. 3d 397; Superior Court of Rhode Island, Vapor Tech Association v 
Raimondo, [2019] C.A. No. PC-2019-10370; Superior Court of Massachusetts, Vaor Tech Association v Baker, [2019] WL 6050041
46 ibid
47 Supreme Court of New York, Matter of Vapor Tech. Assn. v Cuomo, [2020] 118 N.Y.S. 3d 402
48 Superior Court of Rhode Island, Vapor Tech Association v Raimondo, [2019] C.A. No. PC-2019-10370
49 World Trade Organization, Request for the establishment of a panel by Indonesia-United States- Measures affecting the production and sale of clove 
cigarettes, [2010] WT/DS406/1 
regulation in New York was a statement of public 
policy and not the product of biomedical research and 
an order for preliminary injunction was granted. On 
the other hand, the Superior Court of Rhode Island 
deferred to the Department of Health’s assessment 
of the emergent nature of the ‘vaping’ crisis and the 
necessity to enact emergency regulations.48
A precursor to the prohibition of flavoured ENDS can be 
observed in a dispute before the World Trade Organization 
(WTO) concerning the prohibition of flavoured cigarettes.
In US – Clove Cigarettes, Indonesia brought a claim 
before the WTO against the United States concerning 
a law that prohibits cigarettes containing a constituent 
that is a characterizing flavour of tobacco or tobacco 
smoke, other than menthol or tobacco.49 Among other 
things, Indonesia argued that the:
 l law is discriminatory because it treats clove 
cigarettes (primarily produced in Indonesia) less 
favourably than like menthol cigarettes (primarily 
of United States origin), in violation of Article 2.1 of 
the TBT Agreement; and
 l prohibition is not necessary to achieve a legitimate 
objective, such as protection of human life or 
health, and that accordingly, the measure results 
in violation of Article 2.2 of the TBT Agreement.
The Court observed 
that the emergency 
regulations carved 
out an exception for tobacco 
flavour and menthol without 
any evidence that these 
flavours were eliminated from 
the list of substances shown to 
trigger the spate of pulmonary 
diseases in New York.
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With respect to non-discrimination, the United States 
argued that the measure is non-discriminatory 
and that the law draws a distinction between clove 
cigarettes and menthol cigarettes on health grounds 
(rather than based on the origin of the products). 
More specifically, the US argued that clove cigarettes 
are a niche product that is used disproportionately by 
youth, whereas menthol cigarettes are attractive to 
youth and adult smokers in similar proportions and 
are smoked by tens of millions of adults in the United 
States on a regular basis. The United States had also 
argued that a regulatory distinction was drawn between 
clove and menthol cigarettes because the extent of 
menthol consumption in the United States means that 
prohibiting menthol could create significant risks of 
illicit trade as well as problems for the United States 
health system (given the addictive character of nicotine).
The WTO panel found that the US law discriminated 
against cigarettes produced in Indonesia in favour 
of cigarettes produced in the US.50 In upholding the 
Panel Report, the Appellate Body found that the law 
fell heaviest on imported products and was not based 
solely on a legitimate regulatory distinction between 
the two product classes. In the latter respect, the 
Appellate Body emphasized that clove and menthol 
each mask the harshness of tobacco and that clove and 
menthol cigarettes are each attractive to youth.51
The Panel also rejected Indonesia’s argument that the 
prohibition of clove flavoured cigarettes was more trade 
restrictive than necessary under Article 2.2 of the TBT 
Agreement. This aspect of the Panel Report was not 
appealed and subsequent disputes, such as Australia – 
Tobacco Plain Packaging, tend to confirm the scope that 
WTO Members have for tobacco control under Article 2.2.
In this context, the Appellate Body’s approach to non-
discrimination, which asks whether different treatment 
of product categories is based on a legitimate regulatory 
distinction, embraces a continuum of risk approach to 
legal analysis. Put differently, WTO Panels may inquire 
deeply into the relative risks posed by different product 
categories. In this instance, that inquiry occurred in the 
context of a discrimination claim, but a similar approach 
could arise in the context of necessity analysis.
Following the outcome of US - Clove Cigarettes, the 
2014 EU TPD required a prohibition on flavoured 
50 World Trade Organization, Panel Report- United States- Measures affecting the production and sale of clove cigarettes, [2011] WT/DS406/R
51 World Trade Organization, Appellate Body Report- United States- Measures affecting the production and sale of clove cigarettes, [2012] WT/DS406/AB/R
52 Court of Justice of the European Union (CJEU), Republic of Poland v European Parliament & Council of the European Union, [2016] Case C-358-14, 
(https://www.tobaccocontrollaws.org/files/live/litigation/2456/EU_Republic%20of%20Poland%20v.%20European.pdf, accessed 26 July 2019)
53 Federal Court of the Federal District (Brazil), Sinditabaco v ANVISA, [2012] Decision No. 323-B/2012, (https://www.tobaccocontrollaws.org/files/live/
litigation/1098/BR_Sinditabaco%20v.%20ANVISA.pdf, accessed 25 July 2019)
54 Chamber of the Administrative Court (Germany), Menthol Capsule Case, [2012] File Number 5A 206/11, (https://www.tobaccocontrollaws.org/files/
live/litigation/2267/DE_Menthol%20Capsule%20Case.pdf, accessed 25 July 2019)
cigarettes, including menthol. Poland challenged this 
aspect of the EU TPD arguing, among other things, that 
the prohibition violated principles of free movement 
of goods.52 The ECJ was therefore called upon to 
consider the proportionality of the measure. The Court 
first found that flavoured tobacco products share 
objective characteristics that make tobacco products 
more attractive, particularly in the context of initiation. 
The focus of the analysis then shifted to whether 
alternatives proposed by Poland were equally suitable. 
In this respect, the ECJ rejected the argument that 
stricter age limits, country-by-country bans on import 
of flavoured products, and specific health warnings 
were equally suitable and less restrictive measures. 
In some respects, this analysis is similar to application 
of the necessity test in the WTO Panel Report in US 
- Clove Cigarettes. In each instance, adjudicators did 
not find it difficult to justify flavour bans. It was only 
where they were partial in nature (the exemption for 
menthol in the US) that continuum of risk arguments 
gained traction.
Bans on flavours have also been challenged in 
other countries. The most prominent example of 
this, concerning a ban on flavours and additives is 
Sinditabaco v ANVISA.53 In this claim, Sinditabaco 
challenged the authority of ANVISA, the Brazilian 
regulatory agency, to regulate flavours and additives. 
The claim delayed implementation of the regulation, 
but was ultimately unsuccessful. An English translation 
of the Supreme Court ruling is not available.
Similarly, in Germany a manufacturer sought 
permission to import and market a cigarette which 
contained a capsule filled with menthol flavouring 
in the cigarette filter.54 The Office of Consumer 
Protection and Food Safety rejected this request on 
the ground that menthol would soften the unpleasant 
properties of tobacco smoke and thus lead to increased 
consumption. The manufacturer challenged this 
decision of the government agency and argued that the 
product was not a novelty but a further development 
of menthol cigarettes already being sold. The Court 
upheld the agency’s decision. It was noted that there 
was information that the cigarette showed greater 
harmfulness or risk addiction compared to traditional 
cigarettes, and that the attractiveness of smoking this 
cigarette was significantly increased with the new 
capsule technology.
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Where a product category is in the marketplace, 
governments administer laws and regulations with 
respect to those products, including by undertaking 
enforcement actions. Such actions that have led to 
legal disputes include actions against companies 
to implement:
 laws concerning misleading conduct, 
including unsubstantiated claims and false 
claims of endorsement; and
 restrictions on advertising and  
promotion.
This second group of cases is distinct from those 
described above in the sense that the cases reflect 
administration of laws and rules governing the 
marketing of ENDS where the products are available in 
the market (whether legally or not).
55 United States v. Philip Morris USA Inc., 449 F. Supp. 2d 1 (D.D.C. 2006), aff’d in part & vacated in part 566 F.3d 1095 (D.C. Cir.2009) (per curiam), cert. 
denied, 561 U.S. _. 130 S. Ct. 3501 (2010), pp 819 – 864.
56 Australia (Competition and Consumer Act 2010 (Cth), Schedule 2, s 18, (http://classic.austlii.edu.au/au/legis/cth/consol_act/caca2010265/sch2.html, 
accessed 29 July 2019)
57 See https://www.accc.gov.au/media-release/accc-resolves-light-and-mild-cigarette-issue-with-bat-and-philip-morris
Misleading conduct and 
false claims
There is a substantial line of case law concerning 
misleading conduct and false claims with respect to 
cigarettes, particularly relating to use of misleading 
descriptors such as ‘light’ and ‘mild’. In many instances, 
these cases take their lead from action against major 
US tobacco companies under the Racketeering 
Influenced and Corrupt Organization (Act).55
Parties to the WHO FCTC also have international legal 
obligations to prohibit misleading labelling on tobacco 
products (Article 11.1(a)) and misleading tobacco 
advertising, promotion and sponsorship (Article 
13.4 (a)).
However, despite often being marketed with claims 
relating to their relative risk to health, or their potential 
as tobacco cessation devices, there appear to be only 
a few cases in which governments have challenged 
ENDS companies concerning misleading conduct.
A number of these cases come from Australia, where 
the Australian Consumer Law includes a general 
prohibition on misleading or deceptive conduct 
by companies, as well as specific prohibitions on 
misleading representations.56 This law was previously 
used by the Australian Competition and Consumer 
Commission (ACCC) to extract legally enforceable 
undertakings by major tobacco companies not to use 
misleading descriptors with respect to cigarettes.57
ENDS are in effect prohibited as nicotine is a proscribed 
poison in Australia and the ACCC has taken action 
against a number of companies for misleading 
conduct, but in the process sought to restrain the 
a
b
Health claims and 
advertising, promotion, 
and sponsorship2
Where a product 
category is in 
the marketplace, 
governments administer laws 
and regulations with respect 
to those products, including 
by undertaking enforcement 
actions. Such actions have led 
to legal disputes.
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companies from selling ENDS. For example, in ACCC 
v. The Joystick Company58, the ACCC alleged that the 
company in question had engaged in misleading or 
deceptive conduct by representing that e-cigarettes 
for sale by the company did not contain carcinogens, 
toxic substances or formaldehyde and for representing 
that flavours had received the approval of the ACCC. 
The company and its Director accepted the allegations 
and made an undertaking that it would not supply 
e-cigarettes for a period of three years. Similar 
outcomes were achieved in other cases.59
Claims concerning misleading advertising have 
also been submitted to the United Kingdom (UK) 
Advertising Standards Authority (ASA), which 
administers codes of practice concerning how 
businesses should advertise in the UK. For example, 
an ASA adjudication on Nicocigs Ltd. concerned a 
website selling e-cigarettes that claimed ‘vapour’ 
from a particular product was completely harmless 
and that nicotine was mildly addictive, but harmless.60 
In the absence of any substantiation for the claims, 
ASA found them to be misleading under the Code 
and directed the company to ensure that the claims 
no longer appeared in their current form. In the ASA 
adjudication on Ten Motives Ltd.61, it was examined 
whether claims featured on a leaflet for electronic 
cigarettes, “healthier smoking alternative” and “you 
can still enjoy smoking without worrying about 
the effects on your health” were misleading. The 
advertisers had not provided any documentation from 
the Medicines and Healthcare Products Regulatory 
58 Federal Court of Australia, ACCC v. The Joystick Company, [2017] FCA 397, (https://www.tobaccocontrollaws.org/files/live/litigation/2541/AU_
Australian%20Competition%20and%20Con.pdf, (Accessed 5 May 2019)
59 ACCC v. Social-Lites Pty Ltd., [2017] FCA 398, ((https://www.tobaccocontrollaws.org/files/live/litigation/2542/AU_Australian%20Competition%20
and%20C n.pdf, accessed 15 July 2019) and ACCC v Burden, [2017] FCA 399, (https://www.tobaccocontrollaws.org/files/live/litigation/2542/AU_
Australian%20Competition%20and%20Con.pdf, accessed 15 July 2019)
60 ASA Ruling on Nicocigs Ltd., [2013] Complaint Ref: A12-207775, (https://www.tobaccocontrollaws.org/files/live/litigation/1396/GB_ASA%20
Adjudication%20on%20Nicocigs%20L.pdf, accessed 27 June 2019)
61 ASA Adjudication on Ten Motives Ltd., [2014] Complaint Ref: A13-250753, (https://www.tobaccocontrollaws.org/files/live/litigation/1714/GB_ASA%20
Adjudication%20on%20Ten%20Motive.pdf, accessed 27 June 2019)
62 FCTC/COP/6/10 Rev.1 n (6)
63 ibid
Agency (MHRA) to support their claims and they were 
held to be misleading.
Given the claims with which ENDS are commonly 
marketed there are relatively few reported cases 
concerning misleading or false claims. This might 
be attributable to the absence of general consumer 
laws concerning misleading conduct, to domestic 
laws implementing the WHO FCTC provisions typically 
not applying to ENDS, or to a general enforcement 
challenge concerning the number of small-scale 




At the fifth session of the Conference of the Parties 
(COP) to the WHO FCTC, a request was made for WHO 
to examine evidence on the health impacts of ENDS 
and identify options for their prevention and control. 
The report prepared by WHO was considered at the 
sixth session of the COP to the WHO FCTC.62 It was 
recommended that in terms of ENDS advertising, 
promotion and sponsorship, an appropriate 
governmental body must be the regulator.63 In the 
event this was not possible, an outright ban on 
ENDS advertising, promotion and sponsorship was 
encouraged rather than the implementation of a 
voluntary code on ENDS marketing.
Despite often being marketed with claims relating to 
their relative risk to health, there appear to be only 
a few cases in which governments have challenged 
ENDS companies concerning misleading conduct. 
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It was recommended that advertising, promotion and sponsorship of ENDS and ENNDS must, at the minimum:64
a  State clearly whether the product contains 
nicotine or may be used with nicotine solutions;
b  Not make them appealing to or target, either 
explicitly or implicitly, non-smokers or non-
nicotine users, and must therefore indicate that 
ENDS are not suitable for use by people who do 
not currently consume tobacco products;
c  Not make them appealing to or target, either 
explicitly or implicitly, minors, including 
through the selection of media, location or the 
context in which they appear or through imagery 
that promotes sexual or sporting prowess;
d  Never promote ENDS for non-smokers, and 
their use should not be portrayed as a 
desirable activity in its own right;
e  Encourage smoking cessation and provide a 
quit line number if one exists;
f  Contain nothing that could reasonably be 
expected to promote the use of tobacco 
products, such as:
i. the appearance or/and use of tobacco products;
ii. the use of any brand name, design, colour, 
emblem, trademark, logo or trade insignia or any 
other distinctive feature that might be associated 
by the audience with a tobacco product;
iii. the use of the words e-cigarette, electronic 
cigarette, or any other descriptor that might 
reasonably be expected to create confusion 
with the promotion of cigarettes and other 
combustible tobacco products;
iv. showing ENDS products in ways that could 
reasonably be expected to promote tobacco 
products, including images of tobacco-
like products;
g  not contain health or medicinal claims, unless 
the product is licensed for those purposes by 
the appropriate regulatory agency. Electronic 
cigarettes and other nicotine-containing 
products should be presented only as an 
alternative to tobacco, and should include 
warnings that dual use will not substantially 
reduce the dangers of smoking;
h  not undermine any tobacco-control measure, 
including by not promoting the use of ENDS in 
places where smoking is banned;
i  include factual information about product 
ingredients other than nicotine and in a way 
that does not distort evidence of risks;
j  not link these products with gambling, 
alcohol, illicit drugs or with activities or 
locations in which using them would be unsafe 
or unwise.
64 ibid
65 See https://www.asa.org.uk/uploads/assets/uploaded/11ef66e3-3638-4573-a867097d631c7c15.pdf 
66 See https://www.asa.org.uk/uploads/assets/846f25eb-f474-47c1-ab3ff571e3db5910/BCAP-Code-full.pdf
67 ASA Ruling on Mirage Cigarettes Ltd., [2015] Complaint Ref: A15-292291, (https://www.tobaccocontrollaws.org/files/live/litigation/2360/GB_ASA%20
Adjudication%20on%20Mirage%20Cig.pdf, accessed 27 June 2019)
In this respect, the UK Code of Non-broadcast 
Advertising and Direct & Promotional Marketing 
(CAP Code) 65 and the UK Code of Broadcast 
Advertising (BCAP Code)66, incorporates several WHO 
recommendations and sets out a number of rules 
concerning marketing of e-cigarettes. The UK ASA 
has also been called upon to adjudicate a substantial 
number of complaints concerning the compliance of 
electronic cigarette advertising with the CAP and BCAP 
Code. Complaints have concerned whether advertising 
is irresponsible, targets children, indirectly promotes 
tobacco products, targets non-smokers or sexualizes 
electronic cigarettes. For example, a television 
advertisement showed a man handing a woman an 
electronic cigarette, followed by on-screen text that 
stated “CHOICE”, “FLAVOUR” and then “FREEDOM”, 
and ended with the couple in vapour-like clouds.67 In 
this adjudication, the ASA observed that even though it 
was clear that the product featured was an electronic 
cigarette, a strong association with traditional tobacco 
was created through the advertisement. It was held 
that the advertisement indirectly promoted the use 
of tobacco products and breached the CAP Code. In 
another television advertisement for KiK electronic 
cigarettes, a man claimed that he used to smoke 
normal cigarettes but after he quit, he tried electronic 
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cigarettes and preferred them.68 The question before 
the ASA was whether the advertisement breached 
the Code as it would encourage non-smokers and 
particularly former smokers to try electronic cigarettes. 
It was held that the advertisement was irresponsible 
and breached the BCAP Code. The company was 
directed not to encourage ex-smokers or non-nicotine 
users to use e-cigarettes.
Engagements on social media by Vype electronic 
cigarettes were also examined by the UK ASA.69 Vype 
submitted before the ASA that the use of product-
focused hashtags on Instagram, as well as broader 
hashtags, only allowed information about Vype to reach 
users actively seeking it or users seeking information 
around vaping in general. ASA observed that content 
on an Instagram page was not similar to content on 
a marketers’ website, as there were mechanisms on 
social media to push content to consumers. In any case, 
the advertisements contained content that went beyond 
factual information about the product. BAT was directed 
not to publish marketing communications with the 
direct or indirect effect of promoting nicotine-containing 
e-cigarettes and their components which were not 
licensed as medicines.70
The lawfulness of commercial communications 
on social media pages was examined by a court 
in Rome. The National Council of Consumers and 
Users (Association) filed a petition before the court 
for an injunction to revoke the advertising campaign 
promoted by two electronic cigarette manufacturers.71 
The Association argued that Article 21 of the national 
decree (Legislative Decree No. 6 of 12 January 2016) 
prohibited all forms of advertising and/or sponsorship 
of electronic cigarettes. After a perusal of all the 
provisions of the national decree and the EU TPD, the 
court held that in view of the restrictive approach to 
the advertising of electronic cigarettes and liquid refill 
containers taken in the EU TPD, the argument of the 
manufacturers that commercial communications on 
its social media pages be excluded from the scope 
of information society services was untenable. With 
respect to user-generated content, it was held that 
though the e-cigarette manufacturers could not 
68 ASA Adjudication on Vape Nation Ltd., [2014] Complaint Ref: A14-284845, (https://www.tobaccocontrollaws.org/files/live/litigation/2167/GB_ASA%20
Adjudication%20on%20Vape%20Natio.pdf, accessed 27 June 2019)
69 ASA Ruling on British American Tobacco UK Ltd., [2019], (https://www.tobaccocontrollaws.org/files/live/litigation/2710/GB_ASA%20Ruling%20on%20
British%20American.pdf, accessed 27 January 2020)
70 ibid
71 Court of Rome, Civil action n. 57714/2019, XVII Civil Division, (https://www.tobaccocontrollaws.org/files/live/litigation/2706/IT_National%20
Council%20of%20Consumers%20.pdf, accessed 27 January 2020)
72 Commercial Court of Madrid, Altadis v. Philip Morris, [2018] Roj: SJM M 1157/2019 - ECLI: ES:JMM:2019:1157
73 Spain| Law 28/2005|Health measures regarding smoking and its sales regulation, supply, use and advertising of tobacco products, (https://www.
tobaccocontrollaws.org/files/live/Spain/Spain%20-%20Law%2028_2005.pdf, accessed 18 December 2019)
74 The Directorate of Consumer Protection Investigations of the Superintendence of Industry and Commerce (Colombia), Dir. of SIC v Coltabaco S.A.S et al., 
[2019] No. 17-82520—58-0, (https://www.tobaccocontrollaws.org/litigation/decisions/co-20191227-sic-decision-on-iqos-marketing, accessed 8 July 2020)
be held responsible for it, they could not republish 
or promote through links such posts or images on 
their own social media channels. Accordingly, the 
manufacturers were directed to cease all commercial 
communications aimed at promoting the sale of 
electronic cigarettes and refill cartridges and remove 
all unlawful content from their websites and social 
media pages.
To circumvent Spain’s advertising law, Philip Morris 
argued that advertisement of its heat-not-burn device, 
IQOS was not prohibited as it was not a tobacco 
product. A lawsuit was filed against Philip Morris 
alleging that it illegally advertised IQOS along with 
‘Heets’.72 The Court directed Philip Morris to cease 
its campaigning of these products. It was held that 
in the field of tobacco, if the purpose or effect of the 
communication was direct or indirect promotion of 
a tobacco product, then it was violative of the law. 
The isolated advertising of the IQOS device had no 
other purpose than the use of tobacco and would be 
caught within the ambit of the national legislation 
(Law 28/2005).73
The consumer authority in Colombia also examined 
whether prohibition on promotion of tobacco products 
applied to the Philip Morris product IQOS.74 The 
Directorate of Consumer Protection Investigations 
under the Superintendence of Industry and Commerce 
initiated an investigation concerning marketing of IQOS 
after a complaint was received that a picnic festival in 
2017 was sponsored by IQOS. Philip Morris Colombia 
was directed to share information about advertising 
and marketing plans of IQOS in Colombia. The Ministry 
of Health and Social Protection submitted that the IQOS 
devices irrespective of the power source are covered 
by tobacco control legislation of the country. Further, 
the Ministry had demanded compliance with labelling 
and packaging requirements for Heets, but not the 
IQOS device. It was observed by the Directorate that in 
spite of the authority to investigate infractions of the 
tobacco law (No. 1335 of 2009) and apply sanctions, the 
prohibition with respect to advertising, promotion and 
sponsorship do not apply to the IQOS device, as it is not 




The analysis above highlights a number of important observations in the context of regulating novel and emerging nicotine and tobacco products, including:
 ENDS and HTP manufacturers attempt 
to avoid products being regulated so as 
to fall within regulatory or 
legislative gaps;
 manufacturers can be expected to 
deploy arguments concerning the 
relative risk of different product 
categories, and the need for coherent 
regulation along a continuum of risk;
 not all courts are receptive to 
arguments about relative risk, either 
because regulations are justified by 
reference to absolute risk or because 
the concept of relative risk must be 
judged at the population level and 
taking into account factors beyond 
relative toxicity;
 technological advances employed for 
the manufacture of novel and emerging 
nicotine and tobacco products will raise 
questions of whether a product falls 
within the ambit of the national 
legislation of the country;
 there are relatively few cases 
addressing misleading marketing of 
ENDS, or enforcing restrictions on 
advertising, promotion and sponsorship, 
but important cases have been decided, 
including on how social media posts 
may constitute advertising and on 
whether advertising of an HTP device 







Without doubt, other lessons might also be drawn 
from the broader body of case law concerning tobacco 
control. For example, cases challenging application 
of packaging and labelling measures or advertising 
restrictions to other tobacco products will also be 
relevant to application of the same or similar measures 
to ENDS or HTPs. In this respect, the conclusions 
above are drawn from a sub-set of over 1000 judicial 
decisions and are focused narrowly on contemporary 
issues in product regulation.The present paper is 
relevant for countries to analyze the arguments 
presented, and conclusions drawn in different 
jurisdictions in the attempt to assist regulation of novel 
and emerging nicotine and tobacco products in line 
with country-specific public health goals. 

